Global Presence
MSN Laboratories is a global leader in the development and manufacturing of Finished dosage forms. With a strong commitment to quality and excellence, we offer a portfolio of over 400 formulation products and are proud to have 200+ first-to-market generics.
Operating in 100+ countries, we provide high-quality, affordable medicines to millions of patients worldwide. Leveraging advanced technologies, including nanotechnology and offering a wide range of dosage forms, we deliver impactful healthcare solutions across the globe.
Our First to launch Generics
MSN Labs takes pride in being the pioneer of several first in the world drugs in India and globally. We have developed these across a wide range of dosage forms, including tablets (Immediate Release, Sustained/Extended Release, Bi-Layered, Chewable, Dispersible, and Sublingual), capsules (Immediate Release and Delayed Release), and injectables in vials and ampoules. Here are a few of our first in the world generics.
Prasugrel | Bosentan | Febuxostat | Tapentadol | Ambrisentan | Lacosamide | Silodosin | Tolvaptan | Asenapine
Key Therapeutic Areas
Rare Diseases: Addressing Unmet Medical Needs
According to the National Organization for Rare Disorders (NORD), more than 300 million people worldwide are affected by rare diseases. Despite their low prevalence individually, these conditions collectively represent a significant global health challenge, often lacking effective treatment options.
At MSN Laboratories, we are dedicated to making a difference by developing medicines for rare diseases. With a strong focus on innovation and research, we offer solutions for 75+ rare diseases.
Our Commitment to Quality
At MSN Laboratories, we strive to optimize drug development to produce complex generics and specialty drugs that are accessible to patients everywhere. We prioritize not just having the best products but also ensuring they are manufactured through the most advanced and regulatory-compliant processes.
Reliable Formulations
We ensure the highest quality of formulation development, creating reliable, methodically consistent, and regulatory-approved products.
Regulatory Expertise
All our manufacturing units are accredited by leading global regulatory agencies, including USFDA, EMA, PMDA, MHRA, WHO-GMP, and other top authorities, ensuring every product meets the highest international compliance standards.
FDF Manufacturing Capabilities
~ 15 Billion
Tablets
~ 4.0 Billion
Capsules
~120 Million
Sachets
~40 Million
Parenterals
~8.0 Million
Oral Suspensions
~3000 Tons
Granules
